Lorelei M. Skillman - 05 Jan 2023 Form 4 Insider Report for Enfusion, Inc.

Role
Chief Mrktg. & Comm. Officer
Signature
/s/ Matthew Campobasso, as Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
05 Jan 2023
Net transactions value
$0
Form type
4
Filing time
09 Jan 2023, 16:40:56 UTC
Previous filing
27 Oct 2022
Next filing
25 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ENFN Class A Common Stock Award $0 +4,521 +10% $0.000000 49,596 05 Jan 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ENFN Stock Option (Right to Buy) Award $0 +7,474 $0.000000 7,474 05 Jan 2023 Class A Common Stock 7,474 $11.06 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consist of restricted stock units ("RSUs") awarded pursuant to the Enfusion, Inc. 2021 Stock Option and Incentive Plan (the "Plan"). The RSUs will vest in full as follows: 1,507, 1,507, 1,507 RSUs will vest on January 5, 2024, January 5, 2025, and January 5, 2026, respectively.
F2 These options were granted under the Plan and shall become exercisable as follows: 2,492, 2,491, and 2,491 on January 5, 2024, January 5, 2025, and January 5, 2026, respectively.

Remarks:

Exhibit 24 - Power of Attorney